Energy News / Shareholders Foundation, Inc.

NASDAQ:AVEO Shareholder Notice: Lawsuit Alleges False and Misleading Statements by AVEO Pharmaceuticals, Inc.

Via: ReleaseWire

Updated 11:15 AM CDT, Tue, March 12,2019

A lawsuit was filed on behalf of investors in AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) shares over alleged securities laws violations.

San Diego, CA -- (SBWIRE) -- 03/12/2019 -- An investor in shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) filed a lawsuit against AVEO Pharmaceuticals, Inc. over alleged Securities Laws Violations.

Investors who purchased shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) have certain options and for certain investors are short and strict deadlines running. Deadline: April 26, 2019. NASDAQ: AVEO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On January 31, 2019, AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) announced it would not file a New Drug Application for tivozanib (FOTIVDA®). According to AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), the FDA indicated that these "preliminary OS results do not allay their concerns about the potential detriment in OS outlined in the complete response letter dated June 6, 2013.

The plaintiff claims that between August 4, 2016 through January 31, 2019, the defendants made false and/or misleading statements and/or failed to disclose that the TIVO-3 trial was inadequately designed to address the overall survival concerns regarding AVEO's lead candidate drug, tivozanib, from the TIVO-1 trial presented back in the June 2013, that tivozanib had insufficient survival data to obtain U.S. Food and Drug Administration ("FDA") approval following its initial rejection by the FDA in 2013, that this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval, and that as a result, AVEO's public statements were materially false and misleading at all relevant times.

Those who purchased shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqaveo-shareholder-notice-lawsuit-alleges-false-and-misleading-statements-by-aveo-pharmaceuticals-inc-1169011.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com